No Data
The HINSANG GROUP (06893) Shareholder transferred 47 million HKD Market Cap Stocks from Baoqiao Securities to Yuanta Securities Hong Kong, accounting for 22.9%.
On March 3, HINSANG GROUP (06893) Shareholders transferred 47 million HKD Market Cap Stocks from Baokiao Securities Limited to Yuanta Securities Hong Kong, accounting for 22.9%.
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
HINSANG GROUP: Interim Report 2024/2025
hinsang group (06893.HK) mid-term revenue of approximately 46.21 million Hong Kong dollars decreased by about 11.7% year-on-year
On November 28, Hinsang Group (06893.HK) announced that for the six-month interim performance ending on September 30, 2024, the group's revenue was approximately HK$46.21 million, a decrease of about 11.7% from approximately HK$52.3 million in the same period of 2023. The group incurred a loss of HK$19.242 million during this period, a year-on-year increase of 83.9%; with a loss per share of 1.73 HK cents. The group is confident that the Hong Kong market can continue to provide a stable platform for its business growth and expansion. The group remains committed to new product development to enrich its portfolio of health supplements and enhance its brand image as a specialist in health supplements.
HINSANG GROUP: ANNOUNCEMENT ON INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024
Hin Sang Group (International) Holding Expects Wider Net Loss for Six Months to September
More Unpleasant Surprises Could Be In Store For Hin Sang Group (International) Holding Co. Ltd.'s (HKG:6893) Shares After Tumbling 31%
